
Danaher (DHR) Stock Forecast & Price Target
Danaher (DHR) Analyst Ratings
Bulls say
Danaher Corporation has demonstrated a positive trajectory with its performance obligations rising to $4.9 billion in 2Q25 from $4.5 billion in the previous quarter, indicating strong future revenue potential. The company expects a 4.5% growth ramp in its Life Sciences segment for 4Q25, which is supported by favorable comparisons in Genomics and new product launches. Additionally, the anticipated revenue from Cepheid Respiratory for 3Q25 and 4Q25, estimated at $300-350 million and $450-500 million respectively, underscores Danaher's improving market position within the diagnostics industry.
Bears say
Danaher's projected revenue recognition for 2Q25 reflects a decline, with only 46% of obligations expected to be recognized within the next 12 months, down from 48% in the previous quarter. The company faces significant risks related to geopolitical disruptions, foreign exchange volatility, and the potential failure of high-growth end-markets, particularly in China, to recover. Additionally, any changes to the forecasted end-market growth rates could further exacerbate financial performance concerns, highlighting uncertainty in the company's future revenue stability.
This aggregate rating is based on analysts' research of Danaher and is not a guaranteed prediction by Public.com or investment advice.
Danaher (DHR) Analyst Forecast & Price Prediction
Start investing in Danaher (DHR)
Order type
Buy in
Order amount
Est. shares
0 shares